Introduction
Breast cancer is second only to lung cancer as the leading cause of cancer-related deaths in American women (1, 2) . The etiology of most breast cancers remains obscure. In addition to genetic disposition, a significant portion of cancer incidence in the US is related to environmental factors and lifestyles, including diet (3EE7). Consequently, the search for carcinogens that exist in the human environment challenges both scientists and regulatory agencies.
Ubiquitous environmental agents that are known to induce mammary cancer in rodents must be regarded as potential human risk factors and need to be evaluated more closely. An example of such environmental carcinogens is the class of nitropolynuclear aromatic hydrocarbons (NO 2 -PAHs) 3 (8EE10); 6-nitrochrysene (6-NC) is a representative example of this class of carcinogens. The significant carcinogenic activity of 6-NC in the rat mammary gland, its environmental occurrence, the ability of human liver, lung and breast tissue to convert 6-NC into DNA-reactive metabolites, as well as the finding of its hemoglobin adducts in humans suggest that it probably contributes to the development of human breast cancer (11EE16). In fact, several studies reported on the detection of DNA adducts in human breast tissue; however, the nature of these adducts remains unknown (17EE21).
Environmental carcinogens responsible for genomic alterations in human breast cancer have not been defined clearly. 6-NC can be activated by two pathways. The first pathway proceeds via simple nitro-reduction to form N-hydroxy-6-aminochrysene (N-OH-6-AC) that yields three DNA adducts; the structures of these adducts have been characterized (22) (Figure 1 : adducts 1, 2 and 3). The second pathway involves a combination of nitro-reduction and ring-oxidation yielding a very reactive electrophile, trans-1,2-dihydroxy-1,2-dihydro-N-hydroxy-6-aminochrysene, that primarily leads to the formation of a major adduct, yet to be structurally characterized ( Figure 1 : adduct 4). We hypothesized that, in the absence of DNA repair, these adducts will cause mutations in important cancer genes (e.g. p53), and these mutations may lead to the development of breast cancer. Characteristic mutations in human cancer genes can potentially serve as molecular markers of past exposure to specific carcinogens. However, as exposures often arise from complex mixtures, and other factors may also be important in inducing mutations, it is generally difficult to identify`signature mutations' of human carcinogens. Transgenic animals containing retrievable`reporter genes', provide a highly feasible system to identify`signature mutations' of carcinogens that can be compared with mutational spectra of oncogenes or tumor suppressor genes, and such information may be useful in risk assessment. In the present study, we determined the frequencies and types of mutations induced by 6-NC in the cII gene in histologically confirmed normal, non-involved and tumor tissues from the mammary glands of transgenic female rats, following treatment with carcinogenic doses of 6-NC. A follow-up short-term bioassay was initiated to determine the types of 6-NCEEDNA adducts in the rat mammary gland and their possible relationship to different types of mutations.
Materials and methods
Chemicals and enzymes 6-NC was synthesized using the procedure described by Newman and Cathcart (23) . [g-32 P]ATP and T4 polynucleotide kinase were purchased from Amersham Bioscience (Piscataway, NJ). All other enzymes were purchased from Sigma (St Louis, MO).
Animals
Male Big Blue transgenic Fisher 344 rats (BBR) with the genetic background of the F344 strain were purchased from Stratagene (La Jolla, CA) and female SpragueEEDawley rats were purchased from Charles River (Kingston, NY). Rats were housed in an animal facility maintained on a 12-h light/dark cycle, at a constant temperature (22 AE 2 C) and relative humidity (55 AE 15%) controlled room. A total of 96 female (BBR Â CD)F 1 rats were produced by mating two male BBR and six female CD rats. The rats were fed NIH-07 diet during breeding and AIN-76A (high fat) diet after weaning; the latter was used to mimic the Western diet. The presence of the lambda/LIZ shuttle vector in the hybrid rats (which also contains cII gene) was confirmed by the ability of packaged DNA from lacI rats to form phage plaques on Escherichia coli 1250, and the presence of the cII sequence in the phage DNA (see below).
Carcinogenesis assay
At 30 days of age, groups of 31, 14 and 33 of the transgenic rats were treated orally with 6-NC at two dose levels in 500 ml of trioctanoin, or with trioctanoin alone as control once a week for 8 weeks. The carcinogenic doses of 6-NC (total dose: 100 or 200 mmol/rat, respectively) were selected on the basis of our previous bioassays with CD rats (24) . Rats were weighed and palpated weekly after carcinogen treatment to determine the incidence and multiplicity of mammary tumors. Thirty-two weeks after the last carcinogen dose, the rats were decapitated. All animals were necropsied and the mammary glands were examined macroscopically for any gross lesions or abnormalities. Portions of the mammary gland (tumors, non-involved and normal tissues) were stored at À80
C for mutagenesis assays. The remaining mammary tissues were fixed in 10% buffered formalin solution, processed for paraffin sections and stained with hematoxylin and eosin. Histological diagnosis of mammary tumors was based on criteria outlined by Russo et al. (25) .
The cII mutagenesis assay
The BBR contains a lambda shuttle vector that includes the bacterial lacI locus and also the cII gene, which is the target for the mutagenesis studies. It also obviates the potential for ex vivo mutations that could complicate results. This assay detects mutations at the cII locus and possibly the regulator cI locus (26EE30). The cII protein is a positive regulator of gene transcription that controls the decision between lytic or lysogenic development pathways in phage-infected cells. In appropriate E.coli (E.coli 1250) host cells, under specified conditions (25 C) only mutants give rise to phage plaques, whereas at 37 C all infected cells give rise to plaques, providing a phage titer (26EE30). The ratio of mutant to non-mutant plaques is the measure of mutagenesis, the mutant fraction (MF).
Mammary tissue from control and 6-NC-treated rats was ground under liquid nitrogen; the ground tissue was homogenized in a dounce homogenizer, and nuclei were separated by centrifugation. The nuclei were digested with protease K and RNase was added before layering this mixture onto 0.45 m pore-size membranes and dialyzing overnight. After extraction, the DNA was packaged into phage particles using a Transpack phage packaging extract (Stratagene, La Jolla, CA) mixed with the appropriate host strain of E.coli (1250) and assayed for plaque-forming units and mutants (26) . Fifteen to 43 mutants/animal were observed in the 6-NC-treated groups and 10EE21 mutants were seen in each of the control animals. Mammary tissue from eight control rats, 14 low-dose and nine high-dose 6-NC-treated rats was assayed for mutagenesis. The differences between MF in the three groups were analyzed using Student's t-test.
Mutational specificities
Mutant plaques were selected at random, removed from Petri dishes with a wide bore pipette tip and re-suspended in phage buffer. Plaques for amplification and sequencing were taken at random from packaged DNA from 14 different animals from the 6-NC-treated groups and four different rats from the control group. The cII gene in the mutant phages was amplified by PCR of the target region, for which Taq DNA polymerase (Promega, Madison, WI), a forward primer (positions À88 to À66), 5
H and a reverse primer (positions 335 to 358), 5
H were employed. The cII gene length is 294 bp and the total PCR fragment length is 446 bp. The amplified cII gene was purified on a QIAquick PCR-purification column (Qiagen, Valencia, CA), and sequenced by Dr R.Haesevoets (University of Victoria, Canada). Mutations in the cII gene were detected by automated fluorescent DNA cycle sequencing on LI-COR 4200 DNA sequencers (Lincoln, NE). The gene was bi-directionally sequenced. The sequencing primers were:
H . The mutant sequence with the wild-type sequence was compared with SeqMan v5.05 (DNAStar, Madison, WI).
6-NCEEDNA binding assay
We conducted a short-term bioassay using a single dose of 6-NC to determine: (i) whether 6-NCEEDNA adducts can be detected in the mammary gland in vivo in the transgenic rats, (ii) whether the structures of these adducts were identical to those observed in 6-NC-treated non-transgenic CD rats (22) , (iii) whether the individual 6-NCEEDNA adducts persisted to varying degrees after carcinogen treatment and to characterize the relationship between structures of 6-NCEEDNA adducts and mutational specificities in the rat mammary gland. Eighteen female hybrid rats, 30 days of age, were divided into six groups of three rats each and treated orally with a single dose of 6-NC (50 mmol/rat) in 500 ml of trioctanoin, or with trioctanoin alone as vehicle control. Rats were housed and treated with 6-NC under conditions identical to those of the bioassay but to avoid toxicity due to the single treatment, the dose of 6-NC is equivalent to one-half the low dose (100 mmol/rat) used in the bioassay. Rats were killed 24, 48, 72, 168 or 336 h, respectively, after carcinogen treatment. Mammary tissue was excised and stored at À80 C until DNA was isolated and Fig. 1 . Structures of DNA adducts derived from simple nitro-reduction (adducts 1EE3) and adduct 4 derived from a combination of nitro-reduction and ring-oxygenation of 6-NC. The precise structure of adduct 4 remains to be determined.
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quantified by measuring the absorbance at 260 nm (22) . The values of A 260 / A 280 for all DNA samples were 41.8. The yields of mammary DNA ranged from 0.5 to 0.8 mg/g tissue. DNA (20 mg) was hydrolyzed to nucleoside-3 Hmonophosphate and 32 P-postlabeled as described previously; synthetic standards were prepared as described by Chae et al. (22) .
Statistical methods
Tumor incidence was compared among the groups using the x 2 test, adjusted for multiple comparisons with the Bonferroni correction (31) . Tumor multiplicity was compared among the groups using one-way analysis of variance (ANOVA), followed by Tukey's multiple comparisons procedure (32) . Linear regression was used to test for doseEEresponse associations between adduct level and time points. Repeated measures ANOVA models were used to assess group differences in body weights measured over time (33) .
Results
Mammary cancer induction by the oral administration of 6-NC to female (BBR Â CD)F 1 rats The body weights of rats treated with 6-NC were virtually identical to those of control rats over the course of the experiment (data not shown). Survival was 100% in all groups. The incidence and multiplicity of palpable mammary tumor induced by 6-NC (high dose: 57%, 0.92; low dose: 52%, 0.80) were significantly higher (P 5 0.01) than those in control rats (3%, 0.03). Following histopathological examination, both incidence and multiplicity of mammary adenocarcinomas were significantly elevated in the high-dose group (36%, 0.57, P 5 0.01), while in the low-dose group (16%, 0.23, P 5 0.1) they were not statistically significant from those in control rats (3%, 0.03) ( Table I) . On the other hand, the incidence and multiplicity of mammary fibroadenomas were significantly higher in both the high-dose (P 5 0.05) and low-dose (P 5 0.01) 6-NC-treatment groups compared with the control. Rats in the low-and high-dose 6-NC-treatment groups developed 3 and 7% adenomas, respectively; one rat (3%) in the low-dose group had a fibroma; none of these tumors was significantly different from controls.
Mutagenesis
Both the 100 and 200 mmol/rat of 6-NC led to highly significant increases (P 5 0.05) in the MF in mammary tissue compared with spontaneous background levels ( Figure 2) . The low-and high-dose caused the MF to rise about two and three times over background levels, respectively. The difference between the MF induced at the low-and high-dose was not statistically significant. DNA from several 6-NCinduced mammary tumors was also assayed (results not shown) and no difference between MF in tumor and noninvolved tissue was noted.
Mutational specificities A significant difference in the mutational specificities was observed in mammary tissues from control and 6-NC-treated rats (Table II) . Control mutants consisted primarily of GC 3 AT transitions, whereas 6-NC-induced mutants were comprised of several major classes of mutations; GC 3 TA, GC 3 CG, AT 3 CG and AT 3 TA mutations were the most prevalent. Tables III and IV show the positions, sequence context as well as the specific mutations in the cII gene (sequenced from À48 to 294) in DNA isolated from the mammary gland of 6-NC-treated and control rats, respectively. A high percentage of the GC 3 AT transitions in the control animals were located at CpG sites. This is typical for spontaneous mutagenesis in a number of organs in lacI and lacZ rodents in cII, lacI and lacZ genes (34EE37). In cases where identical mutations were observed, the mutants were obtained from different animals (Table III) . Three identical mutations were also observed in mutants from the same animal. These presumably resulted from clonal expansion and only one of these was included in the results. As the mutations were spread among a number of different types there were too few mutants in each category to detect any differences between the highand low-dose groups. Carcinogenesis/mutagenesis induced by 6ENC in rats 6-NCEEDNA binding Figure 3B depicts five DNA adducts that were detected 24 h after 32 P-postlabeling of the mammary tissue of rats treated with 6-NC; these adducts were not detected in the trioctanointreated control ( Figure 3A) . Adducts derived from simple nitroreduction: adduct 1, N-(dG-8-yl)-6-AC; adduct 2, N-(dI-8-yl)6-AC and adduct 3, 5-(dG-N 2 -yl)-6-AC and an adduct resulting from the combination of nitro-reduction and ring oxidation: adduct 4 (compare with Figure 1 ) were identified by comparison of their 32 P-postlabeled autoradiograms with those of synthetic standards (22) . One new adduct (adduct 5) was detected but not identified due to lack of a synthetic standard. Adduct levels decreased with time after carcinogen treatment ( Figure 4) . For each adduct, the test for linear adduct levels over time was significant at P 5 0.01. Adducts 4 and 1 persisted for 1 and 2 weeks, respectively, whereas adducts 2 and 3 were apparently repaired after 3 days. 
In cases where identical mutations were observed, mutants were obtained from different animals. Discussion Studies aimed at defining the relationship between carcinogenesis and mutagenesis, as well as those assessing the relationship between the types (structures) of carcinogenEEDNA adduct and mutation characteristics in the target organ in vivo, are scarce. Toward this end the present investigation reveals for the first time that, following oral administration, 6-NC is capable of inducing mammary tumors in the (BBR Â CD)F 1 rat. In this animal model, mutation frequency parallels carcinogenesis following 6-NC treatment. Of particular importance is that the mutational specificities, exhibited by several major types of mutations in the mammary tissues of rats treated with 6-NC, are consistent with the presence of several types of 6-NCEE DNA adducts in this target organ. Furthermore, the observation that certain types of mutations (e.g. GC 3 TA and AT 3 GC substitutions) in the mammary tissue of rats treated with 6-NC have also been reported in significant percentages among mutations in the p53 gene in human breast tumors (38) suggests a possible contribution of 6-NC to the etiology of this disease. However, to date, environmental agents responsible for genomic alterations in human breast cancer have not been clearly defined.
Mammary cancer induction by 6-NC has been established in numerous investigations conducted previously in our laboratory in female CD rats (13, 24) . In the present investigation, our aim was to determine the relationship between mutagenesis and carcinogenesis in vivo. Prior to the initiation of this study, female CD rats that harbor the lacI gene were not available. Thus, to achieve our goal, commercially available male lacI homozygous BBR and female CD rats were mated to provide sufficient numbers of female (BBR Â CD)F 1 rats. The presence of the lambda/lacI shuttle vector (which also contains cII gene) was confirmed prior to the initiation of bioassays conducted in this study. The doses (100 and 200 mmol of 6-NC/ rat) and the age (30 days) of (BBR Â CD)F 1 rats were identical to those employed in our previous studies with female CD rats (24) . Mammary tumors were induced in the (BBR Â CD)F 1 rats at a somewhat lower incidence than in CD rats (24) . From 30 to 55 days of age, rats are highly susceptible to mammary cancer induction by chemical carcinogens. Russo et al. (39) attributed the high incidence of mammary tumors, obtained upon treatment of virgin rats (30EE55 days of age) with chemical carcinogens such as 7,12-dimethylbenz[a]anthracene, to the existence of undifferentiated terminal end buds whose component cells exhibited a relatively high DNA labeling index.
It is intriguing that the administration of 6-NC to CD rats by intraperitoneal (i.p.) injection elicited adenomas and adenocarcinomas in the colon (40) , while the oral administration led to mammary tumors (13, 24 , and the present study). Thus, organ specificity (mammary cancer versus colon cancer) is dependent on the route of administration (oral versus i.p.), among other factors, including the dose and age of the rat. The precise mechanism that accounts for such organ specificity remains unknown. We used oral administration in this study, because it is more relevant to the route of exposure of humans to environmental NO 2 -PAHs (11, 41) . The present investigation also provides an appropriate animal model system [male and female (BBR Â CD)F 1 rats] to study the relationship between carcinogenesis, mutagenesis (frequency and spectrum) and the type of DNA adducts in the colon of rats when treated i.p. with 6-NC in vivo (40). This is the first report on mutation frequency induced by 6-NC in the mammary gland in vivo. Mutation frequencies were measured at termination (32 weeks) in normal, non-involved and tumor mammary tissues as confirmed by histological examination. The significant elevation in the MF by 6-NC at both dose levels over that in control rats appears to be in line with mammary cancer incidence. Literature data clearly demonstrate that carcinogen-induced mutation frequencies are elevated in tissues that are actual targets for carcinogenesis (42EE47) although certain non-target tissues may also be elevated. These tissues may be initiated, but do not develop tumors during the course of the carcinogenicity assays. Future studies will compare MFs in a non-target organ, such as liver or lymphocytes, with those in the target organ in order to determine factors that can account for susceptibility of the mammary gland to carcinogenesis by 6-NC; lymphocytes can also be utilized in molecular epidemiologic studies (48) as a surrogate for breast tissue. Furthermore, MFs induced by 6-NC at various time points during the progress of the carcinogenesis bioassay require future investigations.
The mutants in DNA from control breast tissue consisted mainly of GC 3 AT transitions. In a previous study aimed at the analysis of MF and mutation specificities in breast tissue of DMBA-treated and control lacI rats, the DNA from controls also revealed mainly GC 3 AT transitions (48) . The origin of these spontaneous mutations remains uncertain, however, deamination of 5-methylcytosine at CpG sites to yield thymine (which then pairs with adenine) has been suggested (34) . The types of mutations found in the mammary tissue of 6-NCtreated rats were different from those found in control animals that received trioctanoin only. The predominant mutations in breast tissue from 6-NC-treated rats were: AT 3 GC (31%), AT 3 TA (24%), GC 3 TA (17%), GC 3 CG (10%) and GC 3 AT (10%). The latter class of mutations may result from spontaneous mutants among those collected from the 6-NC-treated rats. The demonstration of several types of 6-NC-induced mutations is consistent with the observation of different DNA adducts ( Figure 3 ) and with previous results (22) showing that metabolic activation of 6-NC can lead to active electrophiles that can react with dG and dA.
To provide insights into the relationship between the types of 6-NCEEDNA adducts in the rat mammary gland and mutational characteristics described above, we initiated a shortterm study following a single oral administration of 6-NC to female (BBR Â CD)F 1 rats. On the basis of synthetic DNA adduct standards and using the 32 P-postlabeling technique, we characterized several 6-NCEEDNA adducts; all of which have been established previously (22) . These adducts were derived from simple nitroreduction namely N-(deoxyguanosin-8-yl)-6-aminochrysene [N-(dG-8-yl)-6-AC], N-(deoxyinosin-8-yl)-6-aminochrysene [N-(dI-8-yl)-6-AC] and 5-(deoxyguanosin-N 2 -yl)-6-aminochrysene [5-(dG-N 2 -yl)-6-AC], respectively, and from a combination of nitroreduction and ring oxidation (adduct 4); the latter adduct has not yet been fully characterized. The observation of several 6-NC adducts is consistent with the mutational specificities observed in the mammary tissue of 6-NC-treated rats in this study.
In summary, upon comparison with our previous studies that employed CD rats (24) , (BBR Â CD)F 1 rats appear to be less susceptible to mammary cancer induction by 6-NC. The MF appears to follow the same dose response as mammary carcinogenesis induced by 6-NC. The observation of several 6-NCEE DNA adducts appears to be consistent with the mutational specificities, which exhibit several significant classes of mutations. This study also demonstrates that the mutational signature of 6-NC is different from that of spontaneous mutations and also different from that induced by the polyaromatic hydrocarbon benzo[a]pyrene (B[a]P) (38, 49) . Thus, the mutational signature of a NO 2 -PAH (e.g. 6-NC) is distinct from that of PAHs (e.g. B[a]P). An extension of this type of investigation to other carcinogens in target and non-target organs may prove relevant to molecular epidemiological studies aimed at exposure and risk assessment.
